Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy
Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy作者机构：Department of GastroenterologyHospital 12 de OctubreAv Andalucia28041 MadridSpain
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2011年第17卷第12期
页 面：1531-1537页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：Reactivation of hepatitis B is defined as the recurrence or an abrupt rise in hepatitis B virus(HBV) replication,often accompanied by an increase in serum transaminase levels,and both events occurring in a patient with a previous inactive hepatitis B *** reactivation can occur in situations in which the ratio of HBV replication and immune response is *** can happen during the treatment of hemato-oncological malignancies with chemotherapy and in immunosuppression of autoimmune *** manifestations of hepatitis B reactivation are variable and can range from asymptomatic to acute hepatitis,which are sometimes serious and result in acute liver failure with risk of death,and usually occur in the periods between cycles or at the end of *** drugs such as corticosteroids or azathioprine can induce HBV reactivation in patients carrying hepatitis B virus surface antigen(HBsAg) or anti-HBc,but much less frequently than chemotherapy *** tumor necrosis factorαinhibitors infliximab,etanercept and adalimumab may cause reactivation of hepatitis B,and the overall frequency with infliximab may be similar(50%-66%) to that caused by *** HBV serology is recommended for all patients receiving chemotherapy and immunosuppressive drugs,and HBsAg positive patients should receive anti-HBV prophylaxis to decrease virus reactivation and death rates.
维普期刊数据库